PD-L1 t-haNK cell therapy

PD-L1 t-haNK细胞疗法

Report date: 2022/11/20 16:16:13

Base Information

Drug NamePD-L1 t-haNK cell therapy
Drug Alias NamePDL1.t-haNK
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionNatural killer cell replacementsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisHead and Neck Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNantkwest Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio IncNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisHead and Neck Neoplasms +[7] 
Inactive IndicationsTriple Negative Breast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A